Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 8 of 15
Multimodal Machine Learning Characterization of Solid Tumors
Ciprian Catana, MD, PhD
NCT04687969
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
Dana-Farber Cancer Institute
NCT05327452
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Weill Medical College of Cornell University
NCT04422132
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00911118
Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy
Memorial Sloan Kettering Cancer Center
NCT02312401
Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
University of Miami
NCT05842057
Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy
Mayo Clinic
NCT03017794
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
H. Lee Moffitt Cancer Center and Research Institute
NCT04300855
Physical Therapy for Men Undergoing Prostatectomy
Indiana University
NCT02558946
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Alliance Foundation Trials
NCT04335682
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
University of Southern California
NCT02717156
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT03436654
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
University of Michigan Rogel Cancer Center
NCT04194554
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
University of California, San Diego
NCT04349501
CyberKnife Dose Escalation Prostate Cancer Trial
Crozer-Keystone Health System
NCT03822494
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Hoag Memorial Hospital Presbyterian
NCT03889119
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT03173924
Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
Stanford University
NCT04981223
A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04997018
A Study of Telemedicine Shared Medical Appointments (SMAs) Versus Individual Telemedicine Visits for People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05416996
Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men
University of Oklahoma
NCT05331638
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
Medical College of Wisconsin
NCT02177292
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
Weill Medical College of Cornell University
NCT05471414
Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer
University of Arkansas
NCT01514669
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
NCT01342367
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
Dana-Farber Cancer Institute
NCT05918263
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
NCT00329043
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
The New York Proton Center
NCT04842890
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Five Eleven Pharma
NCT03444844
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
Weill Medical College of Cornell University
NCT04506567
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
Memorial Sloan Kettering Cancer Center
NCT05540392
Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer
University of Texas Southwestern Medical Center
NCT02353819
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
NCT04090528
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02452008
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Mark Stein
NCT03689699
A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging
VA Office of Research and Development
NCT03445559
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04030338
Hispanic Adapted and Culturally Relevant Exercising Together
University of Arizona
NCT06018311
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Weill Medical College of Cornell University
NCT00859781
Developing Inclusive Support and Intervention for Spanish-speaking Latiné Prostate Cancer Survivors
Case Comprehensive Cancer Center
NCT06435871
MRI Guided SBRT for Localized Prostate Cancer
Rush University Medical Center
NCT03778112
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT01688492
Clinical Investigation of the da Vinci Surgical System
Intuitive Surgical
NCT05682742
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
OHSU Knight Cancer Institute
NCT05722925
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Amgen
NCT06555796
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
NCT03042468
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT05100472
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.